March industry news: Roche drops late-stage trial of tominersen for Huntington’s disease

Written by Neuro Central

In this month’s industry news round-up: Roche has made the decision to discontinue dosing in the Phase III study of tominersen for Huntington’s disease; mixed results have been reported from a Phase II trial for donanemab in patients with early Alzheimer’s disease; the US FDA has accepted a New Drug Application for atogepant for the preventive treatment of migraine; the European Commission has approved Kesimpta® (ofatumumab) for the treatment of relapsing forms of multiple sclerosis; and the US FDA has approved PONVORY™ (ponesimod) as a treatment for relapsing forms of multiple sclerosis. Take a look at March’s headlines below: Roche...

To view this content, please register now for access

It's completely free